Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001651308-25-000075
Filing Date
2025-05-07
Accepted
2025-05-07 06:09:04
Documents
96
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q bgne-20250331.htm   iXBRL 10-Q 1826607
2 EX-31.1 exhibit311-2025q1.htm EX-31.1 10016
3 EX-31.2 exhibit312-2025q1.htm EX-31.2 10008
4 EX-32.1 exhibit321-2025q1.htm EX-32.1 6348
10 bgne-20250331_g1.jpg GRAPHIC 16225
  Complete submission text file 0001651308-25-000075.txt   8788046

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bgne-20250331.xsd EX-101.SCH 68375
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT bgne-20250331_cal.xml EX-101.CAL 88854
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT bgne-20250331_def.xml EX-101.DEF 276992
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bgne-20250331_lab.xml EX-101.LAB 709906
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bgne-20250331_pre.xml EX-101.PRE 509687
99 EXTRACTED XBRL INSTANCE DOCUMENT bgne-20250331_htm.xml XML 1243188
Mailing Address C/O MOURANT GOVERNANCE SERVICES (CAYMAN) 94 SOLARIS AVENUE, CAMANA BAY GRAND CAYMAN E9 KY1-1108
Business Address C/O MOURANT GOVERNANCE SERVICES (CAYMAN) 94 SOLARIS AVENUE, CAMANA BAY GRAND CAYMAN E9 KY1-1108 13459494123
BeiGene, Ltd. (Filer) CIK: 0001651308 (see all company filings)

EIN.: 981209416 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37686 | Film No.: 25919132
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)